Aptose Biosciences is a clinical-stage biotechnology company developing personalized therapies to address unmet medical needs in oncology, with a particular focus on hematologic malignancies. Aptose is advancing new therapeutics focused on well validated and novel drug targets on the leading edge of cancer research, coupled with validated biomarkers to identify the optimal patient population for our products. The company's small molecule cancer therapeutics pipeline includes products designed for potent single agent activity and to enhance the efficacy of existing anti-cancer therapies without overlapping toxicities. Aptose Biosciences Inc. is listed on NASDAQ under the symbol APTO and on the TSX under the symbol APS.
No articles found.
Bio-Path is a biotechnology company developing targeted therapies for acute myeloi...
Bio-Path is a biotechnology company developing ...
Rocket Pharmaceuticals, Inc. is an emerging, clinical-stage biotechnology company ...
Rocket Pharmaceuticals, Inc. is an emerging, cl...
ILLUSIO is a plastic surgery simulation tool that enables a surgeon and patient to...
ILLUSIO is a plastic surgery simulation tool th...
Outlook Therapeutics is a late clinical-stage biopharmaceutical company focused on...
Outlook Therapeutics is a late clinical-stage b...
Arcturus Therapeutics is developing portfolio of RNA therapeutics for treatment of...
Arcturus Therapeutics is developing portfolio o...
Aurinia is a late clinical stage biopharmaceutical company focused on developing a...
Aurinia is a late clinical stage biopharmaceuti...
Trovagene is a clinical-stage, oncology therapeutics company, taking a precision m...
Trovagene is a clinical-stage, oncology therape...
Mirati Therapeutics (NASDAQ: MRTX) is a San Diego-based clinical-stage biotechnolo...
Mirati Therapeutics (NASDAQ: MRTX) is a San Die...
Join the National Investor Network and get the latest information with your interests in mind.